Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
20 participants
INTERVENTIONAL
2025-12-31
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active LIFU
Active LIFU
In this open label study, all participants will receive active LIFU
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active LIFU
In this open label study, all participants will receive active LIFU
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of ASD (DSM-5)
* Full Scale IQ \> 70
* Verbal communication
* Stable medication for ≥1 month
* Ability to consent or assent with guardian consent
Exclusion Criteria
* Recent investigational drug/device use
* Neurological illness (e.g., epilepsy, TBI)
* Substance use disorder
* Sensory/motor impairments preventing task completion
13 Years
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of General Medical Sciences (NIGMS)
NIH
COBRE in Neurodevelopment and its Disorders (CNDD)
UNKNOWN
Medical University of South Carolina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kevin Caulfield
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin Caulfield, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MUSC Brain Stimulation Offices
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kevin Caulfield, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00146822
Identifier Type: -
Identifier Source: org_study_id